Kaposi's Sarcoma Clinical Trial
Official title:
Cofactors for Classical Kaposi's Sarcoma and for Kaposi's Sarcoma-Associated Herpesvirus Infection: A Case-Control Study in Sicily
Verified date | May 2020 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will try to identify risk factors for Kaposi s sarcoma, a rare skin cancer, and to understand the role of the KSHV virus in development of the disease. All native-born Italians 21 years of age or older residing in Sicily from July 1, 2002 through June 30, 2005 who have Kaposi s sarcoma not related to HIV infection may be eligible for this study. Healthy control subjects will also be enrolled. All participants will be interviewed about their childhood, jobs, habits, medical conditions, and treatments. They also will provide a blood sample and a saliva sample, obtained by swishing a mouthwash for 45 seconds and spitting it into a container. Blood will be tested for two viruses KSHV and HIV that are related to Kapsosi s sarcoma. The KSHV virus is newly discovered and not well understood. In general, a positive KSHV test probably means an infection with the virus has occurred in the past, but not necessarily that disease has developed. HIV is the virus that causes AIDS. People with AIDS have a high risk of Kapsosi s sarcoma. Although HIV and AIDS are very rare among older adults in Sicily, the presence of HIV must be ruled out in order to understand how KSHV is related to Kapsosi s sarcoma. The blood may also be used to measure immunity (the body s defense against infection and cancer) and for genetic studies to help discover why Kapsosi s sarcoma occurs.
Status | Completed |
Enrollment | 1383 |
Est. completion date | May 8, 2020 |
Est. primary completion date | May 8, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | - INCLUSION CRITERIA - CASES: All non-AIDS, pathologically confirmed cases of KS (International Classification of Diseases for Oncology code M9140/3) in native born Italians resident in Sicily from 01 July 2002 through 30 June 2005 (3 years). EXCLUSION CRITERIA - CASES: AIDS, history of organ transplant, no pathologic confirmation, not born in Italy, not resident in Sicily, unable to provide informed consent, age less than 21. INCLUSION CRITERIA - CONTROLS: Native born Italians, resident in Sicily, on the GP's roster. EXCLUSION CRITERIA - CONTROLS: AIDS, history of KS, spouse or relative of an enrolled KS case or of another control, history of organ transplant, not born in Italy, not resident in Sicily, unable to provide informed consent, age less than 21. Exclusion of children. |
Country | Name | City | State |
---|---|---|---|
Italy | Universita Degli Studi Di Palermo | Palermo |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
Italy,
Cottoni F, Masala MV, Budroni M, Rosella M, Satta R, Locatelli F, Montesu MA, De Marco R. The role of occupation and a past history of malaria in the etiology of classic Kaposi's sarcoma: a case-control study in north-east Sardinia. Br J Cancer. 1997;76(11):1518-20. — View Citation
Touloumi G, Hatzakis A, Potouridou I, Milona I, Strarigos J, Katsambas A, Giraldo G, Beth-Giraldo E, Biggar RJ, Mueller N, Trichopoulos D. The role of immunosuppression and immune-activation in classic Kaposi's sarcoma. Int J Cancer. 1999 Sep 9;82(6):817-21. — View Citation
Ziegler JL, Newton R, Katongole-Mbidde E, Mbulataiye S, De Cock K, Wabinga H, Mugerwa J, Katabira E, Jaffe H, Parkin DM, Reeves G, Weiss R, Beral V. Risk factors for Kaposi's sarcoma in HIV-positive subjects in Uganda. AIDS. 1997 Nov;11(13):1619-26. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Kaposi sarcoma (KS) | Kaposi sarcoma | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02201420 -
Evaluation of Technetium Tc 99m Tilmanocept (Lymphoseek®) Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT and SPECT/CT Imaging
|
Phase 2 | |
Terminated |
NCT00686842 -
PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma
|
Phase 1/Phase 2 | |
Completed |
NCT01352117 -
Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma
|
Phase 3 | |
Completed |
NCT01276236 -
Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)
|
Phase 2 | |
Completed |
NCT00001535 -
Twins Study of Gene Therapy for HIV Infection
|
Phase 1 | |
Completed |
NCT01067690 -
Treatment With Indinavir and Chemotherapy for Advanced Classical Kaposi's Sarcoma
|
Phase 2 | |
Completed |
NCT00540566 -
Optical Biopsy of Human Skin in Conjunction With Laser Treatment
|
||
Completed |
NCT00380770 -
HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT
|
Phase 4 | |
Completed |
NCT00001294 -
Genetic Factors and Interrelationships for Sexual Orientation, Susceptibility to HIV and Kaposi's Sarcoma, Alcoholism and Psychological Traits, and Histocompatibility Antigens
|
N/A | |
Completed |
NCT00055237 -
Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients
|
Phase 2 | |
Completed |
NCT00026728 -
Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States
|
N/A | |
Terminated |
NCT00287495 -
BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma
|
Phase 1 | |
Completed |
NCT00581815 -
Spectroscopy With Surface Coils and Decoupling
|
Phase 1 | |
Recruiting |
NCT00006518 -
Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
|
||
Completed |
NCT00001560 -
Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated Cancers
|
N/A | |
Completed |
NCT00982449 -
124I-FIAU Imaging in EBV and KSHV Associated Cancers
|
N/A | |
Recruiting |
NCT03300830 -
Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease
|
||
Completed |
NCT00006171 -
Effects of Potent Antiretroviral Therapy on Kaposi s Sarcoma
|
||
Completed |
NCT02029430 -
A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma
|
Phase 2 | |
Completed |
NCT00026793 -
Assessment of Blood Vessel Density in Kaposi's Sarcoma Lesions
|